Immunodeficiency Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Immunodeficiency stocks.

Immunodeficiency Stocks Recent News

Date Stock Title
Nov 22 BMY AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback
Nov 22 HOOK Hookipa Pharma price target lowered to $7 from $24 at JMP Securities
Nov 22 GILD Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program
Nov 22 HOOK Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program
Nov 21 BMY Major companies that are also popular short-selling stocks
Nov 21 BMY Is Bristol Myers Squibb Stock a Buy?
Nov 21 BMY Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks
Nov 20 GILD Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)
Nov 19 SGMO Sangamo stock climbs 12% post-market on FDA update for ST-503
Nov 19 SGMO Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Nov 19 BMY Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript)
Nov 19 GOVX GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
Nov 19 BMY Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
Nov 19 VIR Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Nov 18 VIR Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
Nov 18 BMY Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
Nov 18 GILD Gilead’s Livdelzi shows promise in PBC clinical trial
Nov 18 BMY Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now?
Nov 18 BMY EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer
Nov 17 BMY Bristol-Myers Squibb: Buy This Bargain Before It's Gone
Immunodeficiency

Immunodeficiency, also known as immunocompromisation, is a state in which the immune system's ability to fight infectious diseases and cancer is compromised or entirely absent. Most cases are acquired ("secondary") due to extrinsic factors that affect the patient's immune system. Examples of these extrinsic factors include HIV infection and environmental factors, such as nutrition.
Immunocompromisation may also be due to genetic diseases/flaws. An example here is SCID.
In clinical settings, immunosuppression by some drugs, such as steroids, can either be an adverse effect or the intended purpose of the treatment. Examples of such use is in organ transplant surgery as an anti-rejection measure and in patients suffering from an overactive immune system, as in autoimmune diseases. Some people are born with intrinsic defects in their immune system, or primary immunodeficiency.A person who has an immunodeficiency of any kind is said to be immunocompromised. An immunocompromised individual may particularly be vulnerable to opportunistic infections, in addition to normal infections that could affect anyone. It also decreases cancer immunosurveillance, in which the immune system scans the body's cells and kills neoplastic ones.

Browse All Tags